Rosiglitazone when added to Glimepiride in patients with diabetes mellitus, has been found to significantly reduce plasma lipid levels and significant improvement in blood glucose control related to a reduction in the insulin resistance.

Rosiglitazone is an anti-diabetes drug used along with a proper diet and exercise program to control high blood sugar in patients with type 2 diabetes. Pioglitazone acts as an insulin sensitizer and decreases the extent of insulin resistance in the body too.

Rosiglitazone increases the permeability of fluid in tiny blood vessels called capillaries. This results in easier movement of fluids across the membrane and their consequent accumulation, resulting in oedema (puffiness). Also, Pioglitazone causes increased sodium and water reabsorption from the kidney that contributes to the oedema.

Rosiglitazone can cause fluid retention and edema. Consequently, there is a lot of fluid in the body (fluid overload). As a result, it may precipitate heart failure (which worsens with fluid overload in those at risk).

Rosiglitazone, either alone or as add-on therapy to conventional treatments, could clinically benefit patients of major depression according to a study